4DMedical Limited saw its share price (ASX: 4DX) close 8.51% lower at A$3.55 today, marking the worst performance on the ASX 200 as markets took profits following a remarkable 501.69% rally over the past year.
The sharp decline extends the decline in 4DMedical shares to 21.81% year-to-date, representing a 30% pullback in the last seven trading sessions. Despite the retreat, the stock remains substantially elevated from levels seen twelve months ago, when the company’s CT:VQ™ technology was in earlier stages of commercialization. Trading volumes surged as markets reassessed valuations following the company’s recent A$150 million capital raising completed at A$3.80 per share on January 15, 2026.
The pullback has pushed shares below the placement price, raising questions about near-term support levels. Technical analysts note that the A$4.00 level, which previously acted as resistance, is now being tested as support following the recent volatility.
4DMedical’s recent capital raising aimed to accelerate commercialization of its CT:VQ™ platform, a medical imaging technology that provides functional lung imaging. The A$150 million injection through institutional placement strengthens the company’s balance sheet significantly, building on a pro forma cash position of A$45.5 million reported as of June 30, 2025, which included A$22.6 million from option exercises.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
The company’s half-year results for the period ended December 31, 2024, demonstrated substantial revenue momentum, with operating revenue surging 265% year-over-year to A$2.90 million. The Software-as-a-Service model showed strong adoption, with 301 sites globally utilizing the platform, a 41% increase from the previous corresponding period.
Strategic partnerships have underpinned the growth trajectory. In December 2025, 4DMedical secured a distribution agreement with Philips that includes a minimum US$10 million order commitment for CT:VQ™ spanning 2026 and 2027. The deal targets accelerated adoption across North America, representing a significant validation of the technology by a major medical equipment manufacturer.
Separately, an expanded partnership with Cleveland Clinic aims to integrate CT:VQ™ into clinical workflows at one of America’s premier medical institutions. The collaboration positions 4DMedical to demonstrate real-world clinical utility in a high-profile healthcare setting, potentially driving broader adoption.
Financial Position and Burn Rate
While revenue growth has been impressive on a percentage basis, absolute revenue levels remain modest relative to the company’s market capitalization. The half-year results also showed increased losses as 4DMedical invests heavily in commercialization infrastructure and market expansion. The recent capital raising provides runway to fund these growth initiatives, though markets will be monitoring cash burn rates closely.
The company’s global footprint expansion demonstrates traction, with site numbers growing steadily. However, converting site installations into recurring revenue at scale remains the critical challenge as 4DMedical transitions from a technology development company to a commercial-stage medical imaging provider.
Outlook
The current share price volatility appears driven primarily by profit-taking after extraordinary gains rather than fundamental deterioration. Markets that drove the stock up more than 500% over twelve months are now recalibrating expectations following the dilutive capital raising and reassessing the pathway to profitability.
The Philips partnership provides tangible revenue visibility through the minimum order commitment, while the Cleveland Clinic collaboration offers clinical validation that could prove instrumental in securing broader U.S. healthcare system adoption. However, competition in medical imaging technology remains intense, with established players possessing significant distribution advantages.
Technical factors may exacerbate near-term volatility, with the stock having attracted momentum-oriented market participants during its rapid ascent. The placement price of A$3.80 represents an immediate overhead resistance level, while support around A$3.50 will be tested if selling pressure continues.
